Tag: Dual orexin receptor antagonist

According to the National Sleep Foundation, as many as 50% of older adults experience difficulty initiating or maintaining sleep. Historically, older sleep medications posed significant risks for this population, but a newer class of drugs has emerged. So, what is the new sleeping pill for the elderly? Newer medications called dual orexin receptor antagonists (DORAs) are offering a safer, more targeted approach to treating insomnia in older adults.

Chronic insomnia affects up to 12% of the adult population in Switzerland, with significant impacts on both physical and mental health. A modern treatment developed by Swiss biopharmaceutical company Idorsia, known as the 'Swiss sleep pill,' is QUVIVIQ (daridorexant), a dual orexin receptor antagonist (DORA) that works differently than traditional sedatives by targeting the brain's wakefulness system.